Rheumatoid Arthritis and Life Expectancy: Modern Outlook

With contemporary treatment, rheumatoid arthritis (RA) no longer significantly shortens life expectancy for most patients. Historical excess mortality (5–10 years) has narrowed dramatically.

Why the Gap Existed

• Uncontrolled inflammation → accelerated atherosclerosis (CVD)
• Infections (immunosuppression, comorbidities)
• Renal/lung involvement (amyloidosis, ILD)
• Treatment toxicity (older regimens)

What Changed

• Early Treat-to-Target: DAS28/CDAI remission goals within 3–6 months.
• DMARDs & Biologics: Methotrexate + TNFi, IL-6i, JAKi, CTLA4-Ig, B-cell depletion—suppress inflammation, prevent joint damage.
• Comorbidity Management: Aggressive CVD risk reduction (statins, BP control, smoking cessation).
• Infection Vigilance: Vaccination (pneumococcal, influenza, COVID, shingles, HBV), TB screening, held biologics during infection.

Residual Risks

• Severe, refractory disease with multi-organ involvement.
• Persistent high disease activity despite therapy.
• Comorbidities: CVD, osteoporosis, malignancy (lymphoma, lung), depression.
• Health disparities: access, adherence, socioeconomic factors.

Optimizing Longevity

1. Early rheumatology referral.
2. Treat-to-target with regular monitoring.
3. Comprehensive comorbidity screening.
4. Lifestyle: exercise, Mediterranean diet, weight management, no smoking.
5. Mental health integration.
6. Shared decision-making; patient education.

RA is a chronic systemic disease, but with modern care, patients can expect near-normal lifespan and quality of life.